LeishmaniasisSEZAMNCT06859619
Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne Diseases
A study testing Peripheral venous blood sample in people with Leishmaniasis and Leptospirosis, run by University Hospital, Montpellier at 1 site in France.
Trial summary
Zoonoses and arboviroses refer to a group of diseases transmitted from animals to humans, either directly or indirectly (via mosquitoes, ticks or contact with contaminated environments). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Leishmaniasis, Leptospirosis, Brucellosis
- What is being tested?
- Peripheral venous blood sample
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 183 participants
- Where
- 1 siteFrance
- Study dates
- 3 Mar 2025to 3 Oct 2025
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18 or over
- Consultant in an infectious diseases department
- Have given written consent to participate in the study
- Working for the City or Metropolis of Montpellier in the Zoo, Espaces Vert or Ecolothèque departments.
Who cannot join
- - Pregnant and breast-feeding women
- Persons benefiting from legal protection measures (guardianship, curatorship, safeguard of justice)
- Participants who are not fluent in French and who do not have a support person capable of reading French.
- Persons unable to express their consent.
- Persons participating in another research project with an exclusion period still in progress.
- Persons not affiliated to a social security scheme or not benefiting from such a scheme.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site
University Hospital Of Montpellier
Montpellier, herault, 34295
CHARLOTTE BOULLE, MD, 04 67 33 52 34 ext. +33, c-boulle@chu-montpellier.fr
About this study
Official title: Seroprevalence of Zoonotic and Arboviral Emerging Infections in Exposed Agents from the City of Montpellier: a Transversal Study.
Zoonoses and arboviroses refer to a group of diseases transmitted from animals to humans, either directly or indirectly (via mosquitoes, ticks or contact with contaminated environments). Most of these diseases are found in certain tropical zones, but global warming and increased international trade are modifying their geographical distribution, with a gradual trend towards temperate regions. A number of these pathogens have already been detected in Occitania, including dengue fever, West Nile, leishmaniasis and Q fever. Given the region's high mosquito population and favorable climatic conditions, other zoonoses have a strong potential to appear in the region, or may already be circulating at a low level. The study focuses on 18 pathogens selected for their potential to emerge and establish themselves in the Occitanie region: Leishmaniasis, Leptospirosis, Brucellosis, Q fever, Rickettsiosis, Tularemia, Psittacosis, Lyme disease, Tick-borne encephalitis, Hantavirus, Hepatitis E virus, Dengue virus, Zika virus, Chikungunya virus, West-Nile virus, Usutu virus, Toscana virus, Crimean-Congo haemorrhagic fever virus.
The aim of the study is to find out whether patients have antibodies against these infectious agents, which would indicate that they have been exposed to them in the past, even in the absence of symptoms.
Describing the circulation of these pathogens will enable to implement appropriate public health measures to avoid the risk of epidemics (mosquito control, informing professionals, etc.), as well as to assess the risk incurred in the workplace and have this risk recognized by the healthcare system.
Read the detailed description
Current environmental changes are influencing the epidemiology of zoonoses, which account for over 75% of emerging infections, with the Mediterranean region being a high-risk area. The proposed study focuses on occupational zoonoses, that is, those that can be contracted in the workplace, through direct contact with animals or exposure to their environment. Some of these zoonoses are recognized and compensable as occupational diseases (OD), while for others, the onus is on the employee to prove the origin of the contamination. The advantages of studying this population are threefold: i) to document occupational risk and improve management and prevention practices in this context, ii) to use this sentinel population - when many of these zoonoses are emerging - to anticipate risks for the less-exposed general population, iii) in the event of the discovery of a positive serology for an infectious agent considered non-circulating in the Occitanie region, to improve the management of symptomatic patients by raising awareness of differential diagnosis. For the purposes of this study, the zoonoses recognized as occupational diseases are: Mediterranean spotted fever, Lyme borreliosis, tularemia, Q fever, brucellosis, psittacosis, hepatitis E and leptospirosis. Although not recognized as occupational diseases, leishmaniasis, hantaviruses, dengue fever, zika, chikungunya, West Nile virus, Usutu, Toscana, Crimean-Congo hemorrhagic fever and tick-borne encephalitis are of particular interest to workers exposed to these diseases, and are also included in the study.
Few data are currently available on the actual rate of circulation of these pathogens in the population of occupationally exposed workers, and none in Occitanie. These outdoor workers also represent a sentinel population, due to their increased exposure, so obtaining precise seroprevalence data in these groups would enable the researchers to anticipate the emergence of these pathogens in the general population in the near future, and to diagnose them individually.
- Conditions
- Leishmaniasis, Leptospirosis, Brucellosis, Q Fever, Rickettsiosis, Tularemia
- Being tested
- Peripheral venous blood sample
- Keywords
- Leishmaniasis,, Leptospirosis, Brucellosis, Zika virus, Q fever, Rickettsiosis, Lyme disease, Tick-borne encephaliti, Hantavirus, Hepatitis E virus, Dengue virus, Chikungunya virus, West-Nile virus, Usutu virus, Toscana virus, Tularemia, Psittacosis, Crimean-Congo haemorrhagic fever virus, epidemiology
- Medical subject headings
- Leishmaniasis, Leptospirosis, Brucellosis, Q Fever, Rickettsia Infections, Tularemia, Psittacosis, Lyme Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Peripheral venous blood sampleOther
Peripheral venous blood sampling for IgG serology against leishmaniasis, leptospirosis, brucellosis, Q fever, rickettsiosis, tularemia, psittacosis, Lyme disease, tick-borne encephalitis, hantavirus, hepatitis E virus, dengue virus, Zika virus, Chikungunya virus, West Nile virus, Usutu virus, Toscana virus, Crimean-Congo hemorrhagic fever virus.
| Study group | Role | What they receive |
|---|---|---|
| City of Montpellier employees working at the Zoo, the Ecolothèque and the Green Spaces Department | Experimental | City of Montpellier employees working at the Zoo, Ecolotheque or green spaces exposed to wildlife by zoo staff and to various vectors (ticks, mosquitoes, sandflies) in the Occitanie region Receives: Other: Peripheral venous blood sample |
What is being measured
The primary outcome is the main question the study is designed to answer.
Estimate seroprevalences of the zoonoses in populations exposed to wildlife by zoo staff and to various vectors (ticks, mosquitoes, sandflies). Leishmaniasis,
prevalence (in percentage) of pathogen IgG positivity against : Leishmaniasis,
Measured: Baseline
Estimate seroprevalences of the zoonoses in populations exposed to wildlife by zoo staff and to various vectors (ticks, mosquitoes, sandflies).Leptospirosis,
prevalence of pathogen IgG positivity against : Leptospirosis,
Measured: Baseline
Estimate seroprevalences of the zoonoses in populations exposed to wildlife by zoo staff and to various vectors (ticks, mosquitoes, sandflies).Brucellosis
prevalence of pathogen IgG positivity against : Brucellosis
Measured: Baseline
Estimate seroprevalences of the zoonoses in populations exposed to wildlife by zoo staff and to various vectors (ticks, mosquitoes, sandflies).Q fever
prevalence of pathogen IgG positivity against : Q fever
Measured: Baseline
Estimate seroprevalences of the zoonoses in populations exposed to wildlife by zoo staff and to various vectors (ticks, mosquitoes, sandflies).Rickettsiosis
prevalence of pathogen IgG positivity against : Rickettsiosis,
Measured: Baseline
Estimate seroprevalences of the zoonoses in populations exposed to wildlife by zoo staff and to various vectors (ticks, mosquitoes, sandflies).Tularemia
prevalence of pathogen IgG positivity against : Tularemia
Measured: Baseline
Estimate seroprevalences of the zoonoses in populations exposed to wildlife by zoo staff and to various vectors (ticks, mosquitoes, sandflies).Psittacosis
prevalence of pathogen IgG positivity against : Psittacosis
Measured: Baseline
Estimate seroprevalences of the zoonoses in populations exposed to wildlife by zoo staff and to various vectors (ticks, mosquitoes, sandflies).Lyme disease,
prevalence of pathogen IgG positivity against : Lyme disease,
Measured: Baseline
Estimate seroprevalences of the zoonoses in populations exposed to wildlife by zoo staff and to various vectors (ticks, mosquitoes, sandflies).Tick-borne encephalitis
prevalence of pathogen IgG positivity against : Tick-borne encephalitis
Measured: Baseline
Estimate seroprevalences of the zoonoses in populations exposed to wildlife by zoo staff and to various vectors (ticks, mosquitoes, sandflies).Hantavirus
prevalence of pathogen IgG positivity against : Hantavirus
Measured: Baseline
Estimate seroprevalences of the zoonoses in populations exposed to wildlife by zoo staff and to various vectors (ticks, mosquitoes, sandflies). Hepatitis E virus
prevalence of pathogen IgG positivity against : Hepatitis E virus
Measured: Baseline
Estimate seroprevalences of the zoonoses in populations exposed to wildlife by zoo staff and to various vectors (ticks, mosquitoes, sandflies).Dengue virus
prevalence of pathogen IgG positivity against : Dengue virus
Measured: Baseline
Estimate seroprevalences of the zoonoses in populations exposed to wildlife by zoo staff and to various vectors (ticks, mosquitoes, sandflies). Zika virus
prevalence of pathogen IgG positivity against : Zika virus
Measured: Baseline
Estimate seroprevalences of the zoonoses in populations exposed to wildlife by zoo staff and to various vectors (ticks, mosquitoes, sandflies).Chikungunya virus
prevalence of pathogen IgG positivity against : Chikungunya virus
Measured: Baseline
Estimate seroprevalences of the zoonoses in populations exposed to wildlife by zoo staff and to various vectors (ticks, mosquitoes, sandflies). West-Nile virus,
prevalence of pathogen IgG positivity against : West-Nile virus,
Measured: Baseline
Estimate seroprevalences of the zoonoses in populations exposed to wildlife by zoo staff and to various vectors (ticks, mosquitoes, sandflies). usutu virus
prevalence of pathogen IgG positivity against : Usutu virus
Measured: Baseline
Estimate seroprevalences of the zoonoses in populations exposed to wildlife by zoo staff and to various vectors (ticks, mosquitoes, sandflies).Toscana virus
prevalence of pathogen IgG positivity against : Toscana virus
Measured: Baseline
Estimate seroprevalences of the zoonoses in populations exposed to wildlife by zoo staff and to various vectors (ticks, mosquitoes, sandflies).Crimean-Congo haemorrhagic fever virus.
prevalence of pathogen IgG positivity against : Crimean-Congo haemorrhagic fever virus.
Measured: Baseline
Secondary outcomes (23)
Determine the factors associated with seropositivity to these diseases. socio-demographic criteria
OR of logistic regression of univariate model between serologies and socio-demographic criteria (age, sex, profession)
Measured: Baseline
Determine the factors associated with seropositivity to these diseases. travel to endemic areas
OR of the logistic regression of the univariate model between serologies and travel to endemic areas for these diseases
Measured: Baseline
Determine the factors associated with seropositivity to these diseases. occupational exposure
OR of the logistic regression of the univariate model between serologies and occupational exposure to these pathologies
Measured: Baseline
Determine the factors associated with seropositivity to these diseases. exposure in private activities
OR of the logistic regression of the univariate model between serologies and exposure in private activities, including the importance of contact with transmission vectors,
Measured: Baseline
Determine the factors associated with seropositivity to these diseases. use of mosquito protection
OR of the logistic regression of the univariate model between serologies and use of mosquito protection,
Measured: Baseline
Determine the factors associated with seropositivity to these diseases.history of transfusion or transplant
OR of the logistic regression of the univariate model between serologies and history of transfusion or transplant
Measured: Baseline
Determine the factors associated with seropositivity to these diseases. comparison of the linear models
AOR of the multivariate logistic regression with the best AIC among all the models tested
Measured: Baseline
Estimating vaccination coverage against leptospirosis in the workplace
prevalence (in percentage) of professional vaccinations for leptospirosis
Measured: Baseline
Estimating vaccination coverage against rabies in the workplace
prevalence (in percentage) of professional vaccinations for rabies
Measured: Baseline
Determine the sensitivity of DBS (dried blood spot) serum neutralization for viral serologies. Dengue virus
Determine the sensitivity (in percentage) of DBS (dried blood spot) seroneutralization for Dengue virus
Measured: Baseline
Determine the specificity of DBS (dried blood spot) serum neutralization for viral serologies. Dengue virus
Determine the specificity (in percentage) of DBS (dried blood spot) seroneutralization for Dengue virus
Measured: Baseline
Determine the specificity of DBS (dried blood spot) serum neutralization for viral serologies. Zika virus
Determine the specificity (in percentage) of DBS (dried blood spot) seroneutralization for Zika virus
Measured: Baseline
Determine the sensitivity of DBS (dried blood spot) serum neutralization for viral serologies. Zika virus
Determine the sensitivity (in percentage) of DBS (dried blood spot) seroneutralization for Zika virus
Measured: Baseline
Determine the sensitivity of DBS (dried blood spot) serum neutralization for viral serologies. Chikungunya virus
Determine the sensitivity (in percentage) of DBS (dried blood spot) seroneutralization for Chikungunya virus
Measured: Baseline
Determine the specificity of DBS (dried blood spot) serum neutralization for viral serologies. Chikungunya virus
Determine the specificity (in percentage) of DBS (dried blood spot) seroneutralization for Chikungunya virus
Measured: Baseline
Determine the sensitivity of DBS (dried blood spot) serum neutralization for viral serologies. West-Nile virus
Determine the sensitivity (in percentage) of DBS (dried blood spot) seroneutralization for West-Nile virus
Measured: Baseline
Determine the specificity of DBS (dried blood spot) serum neutralization for viral serologies. West-Nile virus
Determine the specificity (in percentage) of DBS (dried blood spot) seroneutralization for West-Nile virus
Measured: Baseline
Determine the sensitivity of DBS (dried blood spot) serum neutralization for viral serologies. Usutu virus
Determine the sensitivity (in percentage) of DBS (dried blood spot) seroneutralization for Usutu virus
Measured: Baseline
Determine the specificity of DBS (dried blood spot) serum neutralization for viral serologies. Usutu virus
Determine the specificity (in percentage) of DBS (dried blood spot) seroneutralization for Usutu virus
Measured: Baseline
Determine the sensitivity of DBS (dried blood spot) serum neutralization for viral serologies. Toscana virus
Determine the sensitivity (in percentage) of DBS (dried blood spot) seroneutralization for Toscana virus
Measured: Baseline
Determine the specificity of DBS (dried blood spot) serum neutralization for viral serologies. Toscana virus
Determine the specificity (in percentage) of DBS (dried blood spot) seroneutralization for Toscana virus
Measured: Baseline
Determine the sensitivity of DBS (dried blood spot) serum neutralization for viral serologies. Crimean-Congo haemorrhagic fever virus
Determine the sensitivity (in percentage) of DBS (dried blood spot) seroneutralization for Crimean-Congo haemorrhagic fever virus
Measured: Baseline
Determine the specificity of DBS (dried blood spot) serum neutralization for viral serologies. Crimean-Congo haemorrhagic fever virus
Determine the specificity (in percentage) of DBS (dried blood spot) seroneutralization for Crimean-Congo haemorrhagic fever virus
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Mar 2025
- Study start3 Mar 2025 (estimated)
- Primary completion3 Oct 2025 (estimated)
- Study completion3 Oct 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for LeishmaniasisStudies of the same condition, open and under way.
- More trials run by University Hospital, MontpellierThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- cross-sectional study with minimal risk and constraints
- Masking
- None (open label)
- Enrolment
- 183 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Montpellier
- Sponsor type
- University, hospital or other
- Collaborators
- TransVIHMI UM, IRD UMI233, Inserm U1175, UMR 1058 Pathogenesis & Control of Chronic & Emerging Infections PCCEI
- Responsible party
- Sponsor
- Investigators
- CHARLOTTE BOULLE, MD, Principal investigator, University Hospital, Montpellier
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06859619
- Sponsor's protocol ID
- RECHMPL24_0384
- Acronym
- SEZAM
- Status last verified
- Feb 2025
- First submitted
- 27 Feb 2025
- Last updated
- 5 Mar 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 5 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Seroprevalence of Zoonotic and Arboviral Emerging Infections in Exposed Agents from the City of Montpellier: a Transversal Study.
- ClinicalTrials.gov ID
- NCT06859619
- Acronym / sponsor ID
- SEZAM / RECHMPL24_0384
- Conditions
- Leishmaniasis, Leptospirosis, Brucellosis, Q Fever, Rickettsiosis, Tularemia
- Keywords
- Leishmaniasis,, Leptospirosis, Brucellosis, Zika virus, Q fever, Rickettsiosis, Lyme disease, Tick-borne encephaliti, Hantavirus
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 183 participants (estimated)
- Lead sponsor
- University Hospital, MontpellierUniversity, hospital or other
- Collaborators
- TransVIHMI UM, IRD UMI233, Inserm U1175, UMR 1058 Pathogenesis & Control of Chronic & Emerging Infections PCCEI
- Study start
- 3 Mar 2025 (estimated)
- Primary completion
- 3 Oct 2025 (estimated)
- Study completion
- 3 Oct 2025 (estimated)
- First posted
- 5 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Zoonoses and arboviroses refer to a group of diseases transmitted from animals to humans, either directly or indirectly (via mosquitoes, ticks or contact with contaminated environments). Most of these diseases are found in certain tropical zones, but global warming and increased international trade are modifying their geographical distribution, with a gradual trend towards temperate regions. A number of these pathogens have already been detected in Occitania, including dengue fever, West Nile, leishmaniasis and Q fever. Given the region's high mosquito population and favorable climatic conditions, other zoonoses have a strong potential to appear in the region, or may already be circulating at a low level. The study focuses on 18 pathogens selected for their potential to emerge and establish themselves in the Occitanie region: Leishmaniasis, Leptospirosis, Brucellosis, Q fever, Rickettsiosis, Tularemia, Psittacosis, Lyme disease, Tick-borne encephalitis, Hantavirus, Hepatitis E virus, Dengue virus, Zika virus, Chikungunya virus, West-Nile virus, Usutu virus, Toscana virus, Crimean-Congo haemorrhagic fever virus.
The aim of the study is to find out whether patients have antibodies against these infectious agents, which would indicate that they have been exposed to them in the past, even in the absence of symptoms.
Describing the circulation of these pathogens will enable to implement appropriate public health measures to avoid the risk of epidemics (mosquito control, informing professionals, etc.), as well as to assess the risk incurred in the workplace and have this risk recognized by the healthcare system.
Detailed description
Current environmental changes are influencing the epidemiology of zoonoses, which account for over 75% of emerging infections, with the Mediterranean region being a high-risk area. The proposed study focuses on occupational zoonoses, that is, those that can be contracted in the workplace, through direct contact with animals or exposure to their environment. Some of these zoonoses are recognized and compensable as occupational diseases (OD), while for others, the onus is on the employee to prove the origin of the contamination. The advantages of studying this population are threefold: i) to document occupational risk and improve management and prevention practices in this context, ii) to use this sentinel population - when many of these zoonoses are emerging - to anticipate risks for the less-exposed general population, iii) in the event of the discovery of a positive serology for an infectious agent considered non-circulating in the Occitanie region, to improve the management of symptomatic patients by raising awareness of differential diagnosis. For the purposes of this study, the zoonoses recognized as occupational diseases are: Mediterranean spotted fever, Lyme borreliosis, tularemia, Q fever, brucellosis, psittacosis, hepatitis E and leptospirosis. Although not recognized as occupational diseases, leishmaniasis, hantaviruses, dengue fever, zika, chikungunya, West Nile virus, Usutu, Toscana, Crimean-Congo hemorrhagic fever and tick-borne encephalitis are of particular interest to workers exposed to these diseases, and are also included in the study.
Few data are currently available on the actual rate of circulation of these pathogens in the population of occupationally exposed workers, and none in Occitanie. These outdoor workers also represent a sentinel population, due to their increased exposure, so obtaining precise seroprevalence data in these groups would enable the researchers to anticipate the emergence of these pathogens in the general population in the near future, and to diagnose them individually.
Study design
- Primary purpose
- Screening
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- cross-sectional study with minimal risk and constraints
| Arm | Type | Receives |
|---|---|---|
| City of Montpellier employees working at the Zoo, the Ecolothèque and the Green Spaces Department | Experimental | Other: Peripheral venous blood sampleCity of Montpellier employees working at the Zoo, Ecolotheque or green spaces exposed to wildlife by zoo staff and to various vectors (ticks, mosquitoes, sandflies) in the Occitanie region |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Age 18 or over
- Consultant in an infectious diseases department
- Have given written consent to participate in the study
- Working for the City or Metropolis of Montpellier in the Zoo, Espaces Vert or Ecolothèque departments.
Key exclusion criteria (6 listed)
- - Pregnant and breast-feeding women
- Persons benefiting from legal protection measures (guardianship, curatorship, safeguard of justice)
- Participants who are not fluent in French and who do not have a support person capable of reading French.
- Persons unable to express their consent.
- Persons participating in another research project with an exclusion period still in progress.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Peripheral venous blood samplePeripheral venous blood sampling for IgG serology against leishmaniasis, leptospirosis, brucellosis, Q fever, rickettsiosis, tularemia, psittacosis, Lyme disease, tick-borne encephalitis, hantavirus, hepatitis E virus, dengue virus, Zika virus, Chikungunya virus, West Nile virus, Usutu virus, Toscana virus, Crimean-Congo hemorrhagic fever virus. | Other | City of Montpellier employees working at the Zoo, the Ecolothèque and the Green Spaces Department |
Primary outcome
Estimate seroprevalences of the zoonoses in populations exposed to wildlife by zoo staff and to various vectors (ticks, mosquitoes, sandflies). Leishmaniasis,
Time frame: Baseline
prevalence (in percentage) of pathogen IgG positivity against : Leishmaniasis,
Estimate seroprevalences of the zoonoses in populations exposed to wildlife by zoo staff and to various vectors (ticks, mosquitoes, sandflies).Leptospirosis,
Time frame: Baseline
prevalence of pathogen IgG positivity against : Leptospirosis,
Estimate seroprevalences of the zoonoses in populations exposed to wildlife by zoo staff and to various vectors (ticks, mosquitoes, sandflies).Brucellosis
Time frame: Baseline
prevalence of pathogen IgG positivity against : Brucellosis
Estimate seroprevalences of the zoonoses in populations exposed to wildlife by zoo staff and to various vectors (ticks, mosquitoes, sandflies).Q fever
Time frame: Baseline
prevalence of pathogen IgG positivity against : Q fever
Estimate seroprevalences of the zoonoses in populations exposed to wildlife by zoo staff and to various vectors (ticks, mosquitoes, sandflies).Rickettsiosis
Time frame: Baseline
prevalence of pathogen IgG positivity against : Rickettsiosis,
Estimate seroprevalences of the zoonoses in populations exposed to wildlife by zoo staff and to various vectors (ticks, mosquitoes, sandflies).Tularemia
Time frame: Baseline
prevalence of pathogen IgG positivity against : Tularemia
Estimate seroprevalences of the zoonoses in populations exposed to wildlife by zoo staff and to various vectors (ticks, mosquitoes, sandflies).Psittacosis
Time frame: Baseline
prevalence of pathogen IgG positivity against : Psittacosis
Estimate seroprevalences of the zoonoses in populations exposed to wildlife by zoo staff and to various vectors (ticks, mosquitoes, sandflies).Lyme disease,
Time frame: Baseline
prevalence of pathogen IgG positivity against : Lyme disease,
Estimate seroprevalences of the zoonoses in populations exposed to wildlife by zoo staff and to various vectors (ticks, mosquitoes, sandflies).Tick-borne encephalitis
Time frame: Baseline
prevalence of pathogen IgG positivity against : Tick-borne encephalitis
Estimate seroprevalences of the zoonoses in populations exposed to wildlife by zoo staff and to various vectors (ticks, mosquitoes, sandflies).Hantavirus
Time frame: Baseline
prevalence of pathogen IgG positivity against : Hantavirus
Estimate seroprevalences of the zoonoses in populations exposed to wildlife by zoo staff and to various vectors (ticks, mosquitoes, sandflies). Hepatitis E virus
Time frame: Baseline
prevalence of pathogen IgG positivity against : Hepatitis E virus
Estimate seroprevalences of the zoonoses in populations exposed to wildlife by zoo staff and to various vectors (ticks, mosquitoes, sandflies).Dengue virus
Time frame: Baseline
prevalence of pathogen IgG positivity against : Dengue virus
Estimate seroprevalences of the zoonoses in populations exposed to wildlife by zoo staff and to various vectors (ticks, mosquitoes, sandflies). Zika virus
Time frame: Baseline
prevalence of pathogen IgG positivity against : Zika virus
Estimate seroprevalences of the zoonoses in populations exposed to wildlife by zoo staff and to various vectors (ticks, mosquitoes, sandflies).Chikungunya virus
Time frame: Baseline
prevalence of pathogen IgG positivity against : Chikungunya virus
Estimate seroprevalences of the zoonoses in populations exposed to wildlife by zoo staff and to various vectors (ticks, mosquitoes, sandflies). West-Nile virus,
Time frame: Baseline
prevalence of pathogen IgG positivity against : West-Nile virus,
Estimate seroprevalences of the zoonoses in populations exposed to wildlife by zoo staff and to various vectors (ticks, mosquitoes, sandflies). usutu virus
Time frame: Baseline
prevalence of pathogen IgG positivity against : Usutu virus
Estimate seroprevalences of the zoonoses in populations exposed to wildlife by zoo staff and to various vectors (ticks, mosquitoes, sandflies).Toscana virus
Time frame: Baseline
prevalence of pathogen IgG positivity against : Toscana virus
Estimate seroprevalences of the zoonoses in populations exposed to wildlife by zoo staff and to various vectors (ticks, mosquitoes, sandflies).Crimean-Congo haemorrhagic fever virus.
Time frame: Baseline
prevalence of pathogen IgG positivity against : Crimean-Congo haemorrhagic fever virus.
23 secondary outcomes
Determine the factors associated with seropositivity to these diseases. socio-demographic criteria
Time frame: Baseline
Determine the factors associated with seropositivity to these diseases. travel to endemic areas
Time frame: Baseline
Determine the factors associated with seropositivity to these diseases. occupational exposure
Time frame: Baseline
Determine the factors associated with seropositivity to these diseases. exposure in private activities
Time frame: Baseline
Determine the factors associated with seropositivity to these diseases. use of mosquito protection
Time frame: Baseline
Determine the factors associated with seropositivity to these diseases.history of transfusion or transplant
Time frame: Baseline
Determine the factors associated with seropositivity to these diseases. comparison of the linear models
Time frame: Baseline
Estimating vaccination coverage against leptospirosis in the workplace
Time frame: Baseline
Estimating vaccination coverage against rabies in the workplace
Time frame: Baseline
Determine the sensitivity of DBS (dried blood spot) serum neutralization for viral serologies. Dengue virus
Time frame: Baseline
Determine the specificity of DBS (dried blood spot) serum neutralization for viral serologies. Dengue virus
Time frame: Baseline
Determine the specificity of DBS (dried blood spot) serum neutralization for viral serologies. Zika virus
Time frame: Baseline
Determine the sensitivity of DBS (dried blood spot) serum neutralization for viral serologies. Zika virus
Time frame: Baseline
Determine the sensitivity of DBS (dried blood spot) serum neutralization for viral serologies. Chikungunya virus
Time frame: Baseline
Determine the specificity of DBS (dried blood spot) serum neutralization for viral serologies. Chikungunya virus
Time frame: Baseline
Determine the sensitivity of DBS (dried blood spot) serum neutralization for viral serologies. West-Nile virus
Time frame: Baseline
Determine the specificity of DBS (dried blood spot) serum neutralization for viral serologies. West-Nile virus
Time frame: Baseline
Determine the sensitivity of DBS (dried blood spot) serum neutralization for viral serologies. Usutu virus
Time frame: Baseline
Determine the specificity of DBS (dried blood spot) serum neutralization for viral serologies. Usutu virus
Time frame: Baseline
Determine the sensitivity of DBS (dried blood spot) serum neutralization for viral serologies. Toscana virus
Time frame: Baseline
Determine the specificity of DBS (dried blood spot) serum neutralization for viral serologies. Toscana virus
Time frame: Baseline
Determine the sensitivity of DBS (dried blood spot) serum neutralization for viral serologies. Crimean-Congo haemorrhagic fever virus
Time frame: Baseline
Determine the specificity of DBS (dried blood spot) serum neutralization for viral serologies. Crimean-Congo haemorrhagic fever virus
Time frame: Baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Mar 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Leishmaniasis
RecruitingObservational study
Diagnosis and Treatment of Leishmania Infections
Kinetoplastid, Skin Diseases, Parasitic
Recruiting
Feasibility of Integrating Thermotherapy for Treatment of Cutaneous Leishmaniasis in Primary Health Care Setup
Cutaneous Leishmaniasis
Not yet recruiting
Immersive Technology Headsets to Reduce Procedural Pain and Anxiety: Feasibility and Effects in Cutaneous Leishmaniasis Patients in Pakistan
Cutaneous Leishmaniasis, Pain
RecruitingObservational study
Ex Vivo Immunogenicity Screening of Vaccine Candidate Antigen Combinations in Ethiopian Patients With Leishmaniasis
Leishmaniasis, Cutaneous, Leishmaniasis
Not yet recruitingPhase 2
A Clinical Trial to Investigate Efficacy, Safety and Pharmacokinetics (PK) of Two LXE408 Oral Regimens and Oral Miltefosine as Active Control in Participants Aged ≥ 18 Years Old With Localized Cutaneous Leishmaniasis in the Region of the Americas (AMR).
Localized Cutaneous Leishmaniasis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
CHARLOTTE BOULLE, MD principal investigator
University Hospital, Montpellier
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Peripheral venous blood sample in people with Leishmaniasis and Leptospirosis, run by University Hospital, Montpellier at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 5 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact CHARLOTTE BOULLE, MD (04 67 33 52 34 ext. +33, c-boulle@chu-montpellier.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Estimate seroprevalences of the zoonoses in populations exposed to wildlife by zoo staff and to various vectors (ticks, mosquitoes, sandflies). Leishmaniasis, (time frame: Baseline). The study lists 18 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Mar 2025; AzTrials last refreshed its copy on 8 Nov 2026.